Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
© Drägerwerk AG & Co. KGaA, 2020
Capital Markets PresentationDrägerwerk AG & Co. KGaA
May 2020, Lübeck
© Drägerwerk AG & Co. KGaA, 2020
Disclaimer
2
This presentation contains forward-looking statements regarding the future development of the Dräger Group. These forward-looking statements arebased on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to it to date, and have beenmade to the best of its knowledge and belief. No guarantee or liability for the occurrence of the future developments and results specified can beassumed in respect of such forward-looking statements. Rather, the future developments and results are dependent on a number of factors; they entailrisks and uncertainties beyond our control and are based on assumptions which could prove to be incorrect. Notwithstanding any legal requirements toadjust forecasts, we assume no obligation to update the forward-looking statements contained in this presentation.
This presentation does not constitute an offer of securities for sale or a solicitation of an offer to purchase any securities. No money, securities orother consideration is being solicited by this presentation.
Interim financial reports as well as preliminaries are not audited.
© Drägerwerk AG & Co. KGaA, 2020 3
Outlook
DrägerThe Company
Financials
© Drägerwerk AG & Co. KGaA, 2020 4
protectDräger products
supportsave
lives,
and
© Drägerwerk AG & Co. KGaA, 2020
Net sales developmentStrong growth independent of the global economy
5
Source: International Monetary Fund, World Economic Outlook Database
Dräger net sales in EUR million
Global gross domestic product
Stock-market crash
GulfWar
Mexican pesocrisis
Russianfinancial
crisis
Stock-marketcrash
IraqWar
Financialcrisis
Debtcrisis
2,500
2,000
1,500
1,000
500
0
3,000
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
© Drägerwerk AG & Co. KGaA, 2020
Dräger worldwideNet sales, sites and employees
6
55%
25%
20%
Africa, Asia, Australia
Europe
Americas
Net Sales: EUR
~2.8 billionin 2019
70%
16%
14%
14,845employees
in 2019
Dräger-Sites21%
11%
10%
58%
Sales & Service Production, Quality,Logistics, PurchasingR&D
Administration
Production sites inEurope, America, Africa and Asia
Sales and Service organizations worldwide
SafetyDivision~35 %
MedicalDivision~65 %
© Drägerwerk AG & Co. KGaA, 2020
MarketsOur Customers
7
Fire services Oil and gas industry
Mining Chemical industry
Hospital
Other markets
© Drägerwerk AG & Co. KGaA, 2020
Medical division
8
▪ Infinity Acute Care System
▪ Clincal software solutions
▪ Telemetry and IT-solutions
▪ Medical supply units
▪ Medical Gas supply systems
▪ Medical lights and video solutions
▪ Consumables and accessories
▪ Classical-, Multivendor product service, Professional Service
▪ Training
Anaesthesiology
Ventilation
Thermoregulation
Patient Monitoring & Clinical IT
Workplace Infrastructure
Hospital Consumables & Service
Intensive Care Operating Room Neonatal CareHospital wide
Solutions
✓ ✓
✓ ✓ ✓ ✓
✓ ✓
✓ ✓ ✓ ✓
✓
✓ ✓ ✓ ✓
Note: Market positions based on Dräger‘s market knowledge and its own assessment of market position; positions ranked according to net sales.
▪ Anaesthesia workstations and vaporizers
▪ #1 in Europe and #2 in the US market
▪ Emergency & Transport-, Neonatal- and Intensive Care ventilators
▪ Respiratory monitoring
▪ #1 in Europe
▪ Incubators and Warming Therapy
▪ #2 worldwide and #1 in Europe
© Drägerwerk AG & Co. KGaA, 2020
Safety division
9
Breathing Systems
Gas Detection Systems
Personal Protection Equipment
Impairment Check Equipment
Engineered Solutions
Service
▪ Fixed and mobile gas detection systems
▪ #1 worldwide and #1 in Europe
▪ Alcohol- and drug screeningdevices
▪ Interlock devices
▪ #1 worldwide and #1 in Europe
▪ Protection equipment for hazardous working environments
▪ Body and Head protection, rescue and escape devices, Masks and Filters, etc.
▪ Self-contained BreathingAppartus for fire fighters
▪ #2 worldwide and #1 in Europe
▪ Customer specific solutions
▪ mobile and stationary firefighting training systems
▪ Rescue chambers
▪ Spareparts and consumables
▪ Product Service
▪ Rental, On-site shops and Shutdown Service
▪ Marine-Offshore Service
Note: Market positions based on Dräger‘s market knowledge and its own assessment of market position; positions ranked according to net sales.
Fire Service
✓ ✓ ✓ ✓
Oil & Gas Chemical Mining Other Markets
✓
✓ ✓ ✓ ✓ ✓
✓ ✓ ✓ ✓ ✓
✓ ✓ ✓ ✓ ✓
✓
✓ ✓ ✓ ✓ ✓
© Drägerwerk AG & Co. KGaA, 2020
Medical and safety technology providing long-term growth prospects
10
Hospital
Attractive growth prospects in sizeable markets …
… in developed markets…
… as well as in emerging markets
Oil & Gas Chemical Mining Fire Service
▪ Average expected annual market growth for the global medical equipment market significantly exceeding growth in many other sectors
▪ Strong growth prospects in both developed and emerging markets
▪ Very diversified markets with numerous product and service offerings
▪ Attractive growth prospects for target sectors (e.g. industry) and growing safety investments
▪ Rapidly aging population and consequently increasing healthcare expenditure
▪ Increasing demand for medical equipment to improve clinical workflows and efficiency
▪ Increasingly stricter safety regulations
▪ Rising environmental awareness
▪ Improved outlook for target markets
▪ Strong growth of GDP and population resulting in a demand for improved medical services
▪ Political benefits from investments in health care sector
▪ Increasingly higher safety standards
▪ Increasing industrial hygiene awareness
▪ Strong growth of key customer sectors
© Drägerwerk AG & Co. KGaA, 2020
Strategy for profitable growth
11
Management of innovation rate through continuous improvements in quality and R&D processes
Expansion of market positions in attractive markets. Special focus on profitable growth in developing countries
Expansion of service and consumables business
Investments for future growth
1
2
3
4
© Drägerwerk AG & Co. KGaA, 2020
Technology and innovation leadership to drive profitable growth
12
Strong R&D focus Innovation to enhance future growth (examples)
▪ Approximately 1,300 employees in R&D around the globe.
▪ EUR ~270 million spent for R&D activities in 2019.*
▪ Certified test-center at Lübeck headquartersupports innovation- and approval process.
▪ Qualitymanagement organization with >100 employees.
▪ Very close collaboration with customers to develop new and improve existing products.
▪ Technological competency and high quality standards result in leading market positions and high barriers to entry.
Babyleo ®
Incuwarmer: combination of a
classical incubator and warming bed functionalities.
Dräger X-am® 8000
Multigas detector for measurement of up to 7 gases simultaneously.
*No meaningful capitalization of R&D budget
Atlan®
New anesthesia family with network
connectivity supporting SDC and new user
interface
© Drägerwerk AG & Co. KGaA, 2020
Exploit growth potentials in developing countries
13
Investments in profitable growth
in developing countries
2
▪ Focus on the specific needs of customer in developing countries
▪ Identify growth potential in strong growing markets like China, Brazil and India
▪ Capitalize on the significant investments into the Sales & Service infrastructure and specific
market knowledge, especially in our Region AAA and in Central- and South-America
▪ Enhance engagement with partners in developing countries to expand local presence with R&D,
manufacturing, sales and after sales business
Net sales
Developed Markets76 %
Newly industrialized countries
24 %
Focused product range
Fabius Plus XLVista 120Savina Color
© Drägerwerk AG & Co. KGaA, 2020
Service- and consumables business a clear focus of our sales activities
14
Further expansion of service and consumables
business
3
Dräger Services Dräger Consumables
▪ Functionalities with added value, e.g. optimizing workflow with RFID-based communication between consumables part and therapy machine
▪ Dräger quality to improve hygienic standards
▪ Dräger value add especially in development of consumables. Production usually via suppliers
▪ Partly proprietary consumable products, e.g. Dräger-Tubes
▪ Globally over 3,000 service technicians
▪ Fast and reliable service (repairs and spare parts) is a critical factor for customers
▪ Dräger Service technicians important for customer loyalty
▪ Efficient service solutions via remote service
▪ Broad offerings of product service
▪ New services in the areas of Rental, Multi-Vendor and Marine-offshore
▪ Capitalize on large installed base to expand after sales business
▪ Focus on combined sale of equipment and after sales contracts
▪ Expansion of disposable consumables business
© Drägerwerk AG & Co. KGaA, 2020
Investments will support future growth…
15
WE ARE RESTRUCTURING:
Sales resources
&-capabilities
R&Droadmap
▪ Strengthening Safety sales channels
▪ FGDS System Centers
▪ Key Account Management
▪ Digital distribution channels
▪ Global roll out of Future Technician Workplace
▪ More R&D resources (focus on SW-development)
▪ Partnership with external development partners
▪ Accelerate EM product portfolio
▪ New organizational set-up and business steering according to Medical and Safety:
▪ Introduction of business units with full product and customer accountability.
▪ Business units are combined within a Medical division and a Safety division, each managed by a dedicated board member.
▪ Financial reporting according to the new divisional structure Medical and Safety. (as of FY 2020)
▪ One dedicated board member responsible for the global sales organization.
WE ARE INVESTING:
© Drägerwerk AG & Co. KGaA, 2020 16
Financials
© Drägerwerk AG & Co. KGaA, 2020
Business developmentDräger Group 5y view
17
Note: Restructuring charges included in FY EBIT: EUR 35 million in 2015, EUR 10 million in 2016Dräger Value Added (DVA) = EBIT less cost of capital of average invested capital
Q1 2019 Q1 2020
€ million € million
Net Sales 2,608.90 601.6 640.0
% growth 21.4% 6.4%
% growth (FX adjusted) 20.7% 7.1%
Gross margin 42.3% 44.2%
Functional Expenses -264.0 -281.5
% of Net Sales -43.9% -44.0%
EBIT -10.7 -0.6
EBIT Margin -1.8% -0.1%
DVA -0.6 -22.3
2,572.30 2,595.002,523.80
-1,042.2
-40.2%
62.6
2.4%
2018
€ million
0.9%
3.9%
42.7%
-26.5 49.8
5.4%
2016
€ million
-3.3%
-1.5%
45.0%
66.7
2.6%
44.9%
-1,098.4
-42.1%
-999.2
-39.6%
136.9
-46.3
2017
€ million
1.9%
3.3%
44.8%
2015
€ million
7.2%
2.9%
-992.0
-38.6%
155.7
6.1%
70.7
2019
€ million
2,780.80
7.2%
5.9%
42.7%
-1,116.8
-40.2%
66.6
2.4%
-32.7
© Drägerwerk AG & Co. KGaA, 2020
Key figuresDräger Group 5y view
18
Note: Investments 2015 include EUR ~60m for M&A
© Drägerwerk AG & Co. KGaA, 2020 19
Outlook
© Drägerwerk AG & Co. KGaA, 2020
Guidance 2020
20
Guidance withdrawn:The former guidance does not include the business impact from COVID 19.
The forecast will be renewed in Q2 2020!
+
EXPECTATIONS FOR FISCAL YEAR 2020
2019 2020e
Net sales5.9%
(net of currency effects)
+1.0 - +4.0 %
(net of currency effects)
EBIT margin 2.4% 1.0 - 4.0 %1
Dräger Value Added EUR -32.7 million EUR -70 - +20 million
1 Based on exchange rates at the start of fiscal year 2020
© Drägerwerk AG & Co. KGaA, 2020
Dräger Management
22
At Dräger since 2015
Chairman of the Executive Board CEO
At Dräger since 1992
At Dräger since 2008
At Dräger since 2015
Stefan Dräger
Vice Chairman of the Executive BoardCFO
Gert-Hartwig Lescow
Board member Medical division
Rainer Klug Dr. Reiner Piske
Board member Sales and HR
At Dräger since 2010
Board member Safety division
Anton Schrofner
© Drägerwerk AG & Co. KGaA, 2020
4,0%
67,2%
28,8%
Members of the Dräger family
Dr. Heinrich Dräger GmbH
Free float
Shareholder structure
23
ShareholdingCommon shares
10,160,000 common shares (28.8 % free float)8,600,000 preferred shares (99.0 % free float)
ShareholdingDr. Heinrich Dräger GmbH
18,1%
58,7%
23,2%
Successors of Dr. Heinrich Dräger
Stefan Dräger GmbH
Dräger Foundation
© Drägerwerk AG & Co. KGaA, 2020
IFRS 16 impact
24
in € million
Increase / Improvement as of
December 31,2019
EBITDA 46.8
EBIT 4.4
Cash flow from operating activities 42.4
Net financial debt 107.8
Investments 42.5
Capital employed 100.9
© Drägerwerk AG & Co. KGaA, 2020
Business developmentDräger Group – 5 year view
25
Note: Restructuring charges included in FY EBIT: EUR 35 million in 2015, EUR 10 million in 2016Dräger Value Added (DVA) = EBIT less cost of capital of average invested capital
Q1 2019 Q1 2020
€ million € million
Net Sales 2,608.90 601.6 640.0 6.4
% growth 21.4% 6.4%
% growth (FX adjusted) 20.7% 7.1%
Gross margin 42.3% 44.2%
Functional Expenses -264.0 -281.5 6.6
% of Net Sales -43.9% -44.0%
EBIT -10.7 -0.6 94.6
EBIT Margin -1.8% -0.1%
DVA -0.6 -22.3 >-100.0
2,572.30 2,595.002,523.80
-1,042.2
-40.2%
62.6
2.4%
2018
€ million
0.9%
3.9%
42.7%
-26.5
%
Change
49.8
5.4%
2016
€ million
-3.3%
-1.5%
45.0%
66.7
2.6%
44.9%
-1,098.4
-42.1%
-999.2
-39.6%
136.9
-46.3
2017
€ million
1.9%
3.3%
44.8%
2015
€ million
7.2%
2.9%
-992.0
-38.6%
155.7
6.1%
70.7
2019
€ million
2,780.80
7.2%
5.9%
42.7%
-1,116.8
-40.2%
66.6
2.4%
-32.7
© Drägerwerk AG & Co. KGaA, 2020
Business developmentGroup / Division / Region
26
Dräger-Group 2015 2016 2017 2018 2019 Q1 2019 Q1 2020 Change Change
Net Sales YTD € million € million € million € million € million € million € million % % FX (adj.)
Medical Division 1,698.8 1,647.4 1,668.0 1,643.0 1,741.8 368.4 395.6 7.4 8.0
Safety Division 910.1 876.1 904.3 952.0 1,039.1 233.2 244.4 4.8 5.7
Net Sales 2,608.9 2,523.8 2,572.3 2,595.0 2,780.8 601.6 640.0 6.4 7.1
Europe 1,420.7 1,384.3 1,415.5 1,431.9 1,503.3 326.2 362.7 11.2 11.4
America 509.1 503.7 510.4 499.3 547.7 122.2 120.1 -1.7 -0.4
Africa, Asia, Australia 679.1 635.8 646.4 663.8 729.8 152.7 157.2 2.9 3.9
EBIT 66.7 136.9 155.7 62.6 66.6 -10.7 -0.6 94.4
EBIT-margin (%) 2.6 5.4 6.1 2.4 2.4 -1.8 -0.1
© Drägerwerk AG & Co. KGaA, 2020
Key figuresDräger Group – 5 year view
27
© Drägerwerk AG & Co. KGaA, 2020
Business developmentMedical Q1 - 5 year view
28
Note: The data, including the quarterly figures, can be downloaded from the Dräger website in .xls-format
Medical Division Q1 2016 Q1 2017 Q1 2018 Q1 2019 Q1 2020 Change Change
€ million € million € million € million € million % % FX (adj.)
Net Sales 338.2 336.4 309.9 368.4 395.6 7.4 8.0
Europe 172.9 174.7 167.2 183.2 205.1 12.0 12.2
America 69.2 68.9 62.1 81.8 78.0 -4.7 -3.1
Africa, Asia, Australia 96.1 92.8 80.6 103.4 112.5 8.9 9.3
EBIT -17.0 -7.1 -36.7 -17.2 -6.9 60.2
EBIT-margin (%) -5.0 -2.1 -11.8 -4.7 -1.7
© Drägerwerk AG & Co. KGaA, 2020
Business developmentSafety Q1 - 5 year view
29
Note: The data, including the quarterly figures, can be downloaded from the Dräger website in .xls-format
Safety Division Q1 2016 Q1 2017 Q1 2018 Q1 2019 Q1 2020 Change Change
€ million € million € million € million € million % % FX (adj.)
Net Sales 194.2 198.6 185.7 233.2 244.4 4.8 5.7
Europe 126.8 124.1 120.4 143.5 157.6 9.8 10.3
America 34.7 38.6 31.4 40.4 42.1 4.2 5.0
Africa, Asia, Australia 32.7 35.8 33.9 49.3 44.7 -9.3 -7.2
EBIT 1.3 9.5 -3.1 6.6 6.3 -4.5
EBIT-margin (%) 0.7 4.8 -1.7 2.8 2.6
© Drägerwerk AG & Co. KGaA, 2020
Functional expensesGroup 5 year view
30
Q1 2019 Q1 2020
€ million € million
R&D -63.2 -67.7 7.2
% of Net Sales -10.5% -10.6%
Sales & Marketing -151.2 -159.9 5.7
% of Net Sales -25.1% -25.0%
Administration -49.5 -53.9 8.7
% of Net Sales -8.2% -8.4%
SG&A -200.7 -213.7 6.5
% of Net Sales -33.4% -33.4%
Functional Expenses total -264.0 -281.5 6.6
% of Net Sales -43.9% -44.0%
Headcount1 14,603 14,900 2.0 1 Values as of reporting date
2018
€ million
-252.2
-9.7%
-592.6
-22.8%
-198.5
-7.6%
-791.1
-30.5%
-1,042.2
-40.2%
14,399
-207.4
-8.2%
2016
€ million
-219.0
-8.7%
-554.7
-22.0%
Change
%
-231.1
-8.9%
-611.0
-23.4%
-250.2
-9.6%
2015
€ million
-39.6%
-999.2
13,936 13,263
-861.2
-33.0%
-1,098.4
-42.1%
-762.1
-30.2%
2017
€ million
-234.7
-9.1%
-566.3
-22.0%
-197.7
-7.7%
-764.0
-29.7%
-992.0
-38.6%
13,739
-22.4%
-219.4
-7.9%
-841.3
-30.3%
-1,116.8
-40.2%
14,845
2019
€ million
-263.7
-9.5%
-621.9
© Drägerwerk AG & Co. KGaA, 2020
Cash flow statement5 year view
31
Change
%
Group net profit 33.3 81.7 98.5 34.9 33.8 -3.2
Change in inventories -5.4 17.4 -30.0 -76.9 -24.5 68.1
Change in receivables -44.6 31.3 -22.4 -41.0 0.4 >+100
Change in payables -22.8 -10.2 22.2 -2.3 3.9 >+100
Depreciation and amortization 84.2 85.8 84.2 85.3 127.1 49.1
Other operating cash flow items -4.8 -10.6 -9.3 4.2 23.7 >+100
Operating cash flow 39.9 195.3 143.3 4.1 164.4 >+100
Investing cash flow -167.0 -77.3 -65.5 -63.5 -62.1 2.3
Free cash flow -127.1 118.1 77.8 -59.4 102.4 >+100
Financing cash flow -1.3 -70.0 -41.9 -6.2 -87.9 >-100
Change in cash1 -128.4 48.1 35.9 -65.6 14.5 >+100
Cash and cash equivalents2 172.8 221.5 247.6 179.6 196.3 9.3
1 Change in cash and cash equivalents, i.e. without any effect of exchange rates
2 Values as of reporting date
2019
€ million
2017
€ million
2016
€ million
2015
€ million
2018
€ million
© Drägerwerk AG & Co. KGaA, 2020
Balance sheet
32
31 Dec 2018 31 Dec 2019 Change
€ million € million %
Intangible Assets 336.0 334.0 -0.6
Property, plant and equipment
(incl. Right-of-use assets) 429.1 526.3 22.6
Other noncurrent assets 168.6 201.2 19.3
Noncurrent assets 933.7 1,061.4 13.7
Inventories 459.2 485.2 5.7
Trade receivables 703.9 710.7 1.0
Other current assets 133.9 117.3 -12.4
Cash and cash equivalents 179.6 196.3 9.3
Current assets 1,476.5 1,509.5 2.2
Total assets 2,410.2 2,570.9 6.7
© Drägerwerk AG & Co. KGaA, 2020
Balance sheet
33
31 Dec 2018 31 Dec 2019 Change
€ million € million %
Equity 1,080.7 1,076.4 -0.4
Liabilities from participation certificates 24.8 26.0 4.6
Provisions for pensions and similar obligations 339.3 390.9 15.2
Noncurrent interest bearing loans 125.1 118.6 -5.2
Other noncurrent liabilities 117.0 212.5 81.6
Noncurrent liabilities 606.2 748.0 23.4
Current Provisions 201.3 215.1 6.9
Current loans and liabilities to banks 90.1 51.0 -43.4
Trade payables 201.4 205.1 1.8
Other current liabilities 230.5 275.4 19.4
Current liabilities 723.3 746.6 3.2
Total equity and liabilities 2,410.2 2,570.9 6.7
© Drägerwerk AG & Co. KGaA, 2020
Earnings per share
34
+
=
PCs = participation certificates (Genussscheine)
2017 2018 2019
Net profit (less the share of earnings attributable to non-controlling interests)
'000 € 98,530 34,355 33,350
Scenario: 100% pay-out ratio 100% 100% 100%
tax benefit from pay-out to PCs* '000 € 9,493 3,302 3,205
Earnings attrib. to shares and PCs (incl. tax benefit) '000 € 108,023 37,657 36,555 100%
Earnings attributable to PCs** '000 € 34,420 11,973 11,621 32%
Earnings attributable to shares '000 € 73,603 25,685 24,934 68%
EPS (common share) € 4.12 1.42 1.38
EPS (preferred share) € 4.18 1.48 1.44
Scenario: actual/proposed pay-out ratio 11.6% 12.7% 13.0%
tax benefit from pay-out to PCs* '000 € 960 341 341
Earnings attrib. to shares and PCs (incl. tax benefit) '000 € 99,490 34,696 33,691 100%
Earnings attributable to PCs** '000 € 3,482 1,236 1,236 4%
Earnings attributable to shares '000 € 96,008 33,460 32,455 96%
EPS (common share)*** € 5.38 1.86 1.80
EPS (preferred share)*** € 5.44 1.92 1.86
* tax benefit arises from the tax deductible pay-out to the PCs; please refer to Annual Report 2019, note 19
** without minimum dividend (as interest, the mimimum dividend is already included in net earnings)
*** the EPS is not calculated in accordance with IAS 33
© Drägerwerk AG & Co. KGaA, 2020
Innovation share
35
Share on new products and upgrades medical1
1 Launched in the last 3 years; products are regarded as new, if they enable Dräger to either enter a new market segment or if products are regarded as completely new according to Dräger‘s customers and Dräger‘s sales force. Upgrades are those products, which serve existing Dräger markets, but their functionality is perceived as significantly enhanced by Dräger‘s customers and Dräger‘s sales force.
New products
Upgrades
Net sales
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
20%
7%
2015
27%
25%
2019
5%
30%
22%
2014
10%
32%
18%
2%
2016
20%
21%
3%
2017
24%
23%
5%
2018
28%
© Drägerwerk AG & Co. KGaA, 2020
Financial calendar
36
Dräger publishes preliminary results approximately 2 weeks before the dates of the quarterly reports. Preliminary results for the full year are published in January.
March 5, 2020 Final 2019 figuresConference call
April 30, 2020 Report for the first three months 2020 Conference call
August 13, 2020 Report for the first six months 2020 Conference call
September 30, 2020 (Virtual) Annual shareholders' meeting, Lübeck, Germany 2020 Conference call
October 29, 2020 Report for the first nine months 2020 Conference call
© Drägerwerk AG & Co. KGaA, 2020
Contact
37
Melanie Kamann Thomas Fischler Franziska Ressel
Head of Communications Head of Treasury & Investor Relations Treasury & Investor Relations
Drägerwerk AG & Co. KGaA Drägerwerk AG & Co. KGaA Drägerwerk AG & Co. KGaA
Moislinger Allee 53−55 Moislinger Allee 53−55 Moislinger Allee 53−55
23558 Lübeck, Germany 23558 Lübeck, Germany 23558 Lübeck, Germany
Tel. +49 451 882-3998 Tel. +49 451 882-2685 Tel. +49 451 882-6133
Fax +49 451 882-3944 Fax +49 451 882-3296
Mobile +49 170 8558152 Mobile +49 151 12245295
[email protected] [email protected] [email protected]
www.draeger.com www.draeger.com www.draeger.com